The role of FDG PET in the management of lymphoma: what is the evidence base?

Nucl Med Commun. 2007 May;28(5):335-54. doi: 10.1097/MNM.0b013e3280895e23.


[18F]Fluorodeoxyglucose positron emission tomography (18F-FDG PET) is playing an increasing role in the management of both Hodgkin and non-Hodgkin lymphoma, offering potential advantages in the accuracy of disease assessment at a number of points in the management pathway. This review evaluates the current level of confidence in the use of PET technology in (1) initial staging, (2) the assessment of early response to chemotherapy, (3) the assessment of residual masses at completion of initial treatment, (4) follow-up, and (5) radiotherapy planning.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic / trends*
  • Evidence-Based Medicine / trends*
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymphoma / diagnostic imaging*
  • Lymphoma / therapy*
  • Positron-Emission Tomography / methods
  • Positron-Emission Tomography / trends*
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians' / trends
  • Prognosis
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18